Yes, Aimovig Treats Migraine Prevention
Aimovig (erenumab-aooe) is an FDA-approved prescription medication specifically for preventing migraines in adults.[1] It targets the calcitonin gene-related peptide (CGRP) receptor, a protein involved in migraine attacks, to reduce their frequency. The FDA approved it in 2018 as the first drug in its class for this use.[1]
How Does Aimovig Work for Migraines?
Aimovig is a monoclonal antibody given as a monthly self-injection under the skin. Clinical trials showed it cut monthly migraine days by 50% or more for about half of patients, compared to placebo.[2] It does not treat acute migraine attacks—doctors pair it with drugs like triptans for those.
Who Can Use Aimovig and When Do Doctors Prescribe It?
It's for adults with at least four migraine days per month who haven't responded well to other preventives like beta-blockers or topiramate.[1] Not approved for children or cluster headaches. Prescribers check for conditions like high blood pressure, as it may worsen them.
Common Side Effects Patients Report
Most people tolerate it well, but injection-site reactions (pain, redness) affect up to 45%.[2] Other issues include constipation (up to 10%) and rare allergic reactions like rash or swelling. Long-term data shows no major new risks after years of use.[2]
How Aimovig Compares to Other Migraine Preventives
Unlike older options (e.g., propranolol, which broadly affects blood vessels), Aimovig specifically blocks CGRP with fewer systemic effects.[3] Newer rivals like Emgality (galcanezumab) or Ajovy (fremanezumab) also target CGRP but bind the ligand, not the receptor. Nurtec (rimegepant) adds acute and preventive options in a pill form.
| Drug | Target | Dosing | Avg. Monthly Migraine Reduction |
|------|--------|--------|--------------------------------|
| Aimovig | CGRP receptor | Monthly injection | 3-4 days[2] |
| Emgality | CGRP ligand | Monthly injection | 4-5 days[3] |
| Botox | Nerve signals | Every 12 weeks | 8-9 days (chronic migraines)[3] |
Cost and Access for Patients
List price is about $800 per monthly dose, but insurance often covers most with prior authorization.[4] Patient assistance programs from Amgen (the maker) help uninsured users. No generic yet—patents run through 2033 in the US, per DrugPatentWatch.com.[5]
When Does Aimovig's Patent Expire?
Key US patents expire in May 2033, with pediatric exclusivity possibly extending to 2034. No major challenges listed yet on DrugPatentWatch.com, delaying biosimilars.[5]
Sources
[1]: FDA Approval Label for Aimovig
[2]: Aimovig Clinical Trial Data (NEJM)
[3]: American Headache Society Guidelines
[4]: GoodRx Pricing Data
[5]: DrugPatentWatch.com - Aimovig Patents